Lamotrigine (All indications) updated on 04-22-2025

ASD (Autism spectrum disorder): Diagnosis

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S16195
R67125
Hernandez-Diaz (Lamotrigine) (Epilepsy), 2024 Autism spectrum disorder (ASD) - At least two visits with codes for ASD - Median follow-up was 2 years 2nd and/or 3rd trimester retrospective cohort (claims database) unexposed, sick Adjustment: Yes 0.93 [0.60;1.44] 32/3,134   102/8,815 134 3,134
ref
S17412
R73050
Madley-Dowd_SE (Lamotrigine) (Controls unexposed, general pop) (Mixed indications), 2024 Autism - ICD-8/9/10 codes - Mean 5-20 years old (according groups) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Partial overlapping 0.83 [0.69;0.99] 134/5,035   68,788/2,651,210 68,922 5,035
ref
S17413
R73056
Madley-Dowd_SE (Lamotrigine) (Controls unexposed, sibling) (Mixed indications), 2024 Autism - ICD-8/9/10 codes - Mean 5-20 years old (according groups) during pregnancy (anytime or not specified) population based cohort retrospective sibling excluded Adjustment: Yes Partial overlapping 0.76 [0.50;1.16]
excluded (control group)
-/-   -/- - -
ref
S17266
R72282
Madley-Dowd_UK (Lamotrigine) (Controls unexposed, general pop) (Mixed indications), 2024 Autism - ICD10 codes - Median 6.18 (3.53-9.94) years old during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes 1.10 [0.67;1.78] 20/939   7,657/514,066 7,677 939
ref
S17274
R72306
Madley-Dowd_UK (Lamotrigine) (Controls unexposed, sibling) (Mixed indications), 2024 Autism - ICD10 codes - Median 6.18 (3.53-9.94) years old during pregnancy (anytime or not specified) retrospective cohort (claims database) sibling excluded Adjustment: Yes 1.21 [0.55;2.68]
excluded (control group)
-/-   -/- - -
ref
S12727
R48005
Bjørk (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2022 Diagnosis of childhood autism (F84.0), atypical autism (F84.1), and Asperger syndrome (F84.5) - Median follow up lamotrigine 5.1 (2.4-8.5) years old during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) excluded Adjustment: Yes 1.13 [0.91;1.40]
excluded (control group)
82/7,950   38,437/4,463,879 38,519 7,950
ref
S12728
R48008
Bjørk (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2022 Diagnosis of childhood autism (F84.0), atypical autism (F84.1), and Asperger syndrome (F84.5) - Median follow up lamotrigine 5.1 (2.4-8.5) years old during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: No Controls: epilepsy indication 0.83 [0.65;1.07] C 82/7,950   267/21,634 349 7,950
ref
S8978
R30437
Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 Diagnosis Pervasive developmental disorders (F84) (mean age of 3.6 years old) during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes 1.30 [0.70;2.40] 10/2,813   4,254/1,707,707 4,264 2,813
ref
S8933
R35207
Bromley (Lamotrigine) (Controls unexposed, disease free), 2013 Autistic Spectrum Disorders (at 6 years old) during pregnancy (anytime or not specified) prospective cohort unexposed, disease free excluded Adjustment: No 1.81 [0.20;16.76] C
excluded (control group)
1/30   4/214 5 30
ref
S8936
R35208
Bromley (Lamotrigine) (Controls unexposed, sick), 2013 Autistic Spectrum Disorders (at 6 years old) during pregnancy (anytime or not specified) prospective cohort unexposed, sick Adjustment: No 2.68 [0.10;68.88] C 1/30   0/26 1 30
ref
Total 6 studies 0.88 [0.77;1.00] 81,347 19,901
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Hernandez-Diaz (Lamotrigine) (Epilepsy), 2024Hernandez-Diaz, 2024 1 0.93[0.60; 1.44]1343,1349%ROB confusion: moderateROB selection: moderateROB classification: moderateROB missing: criticalROB mesure: criticalROB reporting: moderate Madley-Dowd_SE (Lamotrigine) (Controls unexposed, general pop) (Mixed indications), 2024Madley-Dowd_SE, 2024 2 0.83[0.69; 0.99]68,9225,03552%ROB confusion: seriousROB selection: lowROB classification: lowROB missing: lowROB mesure: criticalROB reporting: moderate Madley-Dowd_UK (Lamotrigine) (Controls unexposed, general pop) (Mixed indications), 2024Madley-Dowd_UK, 2024 3 1.10[0.67; 1.78]7,6779397%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: unclearROB mesure: criticalROB reporting: moderate Bjørk (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2022Bjørk, 2022 4 0.83[0.65; 1.07]3497,95027%ROB confusion: unclearROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020Coste, 2020 5 1.30[0.70; 2.40]4,2642,8134%ROB confusion: moderateROB selection: moderateROB classification: criticalROB missing: moderateROB mesure: criticalROB reporting: moderate Bromley (Lamotrigine) (Controls unexposed, sick), 2013Bromley, 2013 6 2.68[0.10; 68.88]1300%ROB confusion: criticalROB selection: lowROB classification: lowROB missing: moderateROB mesure: moderateROB reporting: moderate Total (6 studies) I2 = 0% 0.88[0.77; 1.00]81,34719,9010.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Lamotrigine) (Epilepsy; 2: Lamotrigine) (Controls unexposed, general pop) (Mixed indications; 3: Lamotrigine) (Controls unexposed, general pop) (Mixed indications; 4: Lamotrigine) (Controls unexposed, sick) (Mixed indications; 5: Lamotrigine) (Controls unexposed NOS) (Mixed indications; 6: Lamotrigine) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.88[0.77; 1.00]81,34719,9010%NAHernandez-Diaz (Lamotrigine) (Epilepsy), 2024 Madley-Dowd_SE (Lamotrigine) (Controls unexposed, general pop) (Mixed indications), 2024 Madley-Dowd_UK (Lamotrigine) (Controls unexposed, general pop) (Mixed indications), 2024 Bjørk (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2022 Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 Bromley (Lamotrigine) (Controls unexposed, sick), 2013 6 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.94[0.73; 1.20]80,8638,78727%NAMadley-Dowd_SE (Lamotrigine) (Controls unexposed, general pop) (Mixed indications), 2024 Madley-Dowd_UK (Lamotrigine) (Controls unexposed, general pop) (Mixed indications), 2024 Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 3 unexposed, sickunexposed, sick 0.86[0.69; 1.07]48411,1140%NAHernandez-Diaz (Lamotrigine) (Epilepsy), 2024 Bjørk (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2022 Bromley (Lamotrigine) (Controls unexposed, sick), 2013 3 Tags Adjustment   - No  - No 0.84[0.66; 1.08]3507,9800%NABjørk (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2022 Bromley (Lamotrigine) (Controls unexposed, sick), 2013 2   - Yes  - Yes 0.89[0.76; 1.04]80,99711,9210%NAHernandez-Diaz (Lamotrigine) (Epilepsy), 2024 Madley-Dowd_SE (Lamotrigine) (Controls unexposed, general pop) (Mixed indications), 2024 Madley-Dowd_UK (Lamotrigine) (Controls unexposed, general pop) (Mixed indications), 2024 Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 4 Controls   - epilepsy indication  - epilepsy indication 0.83[0.65; 1.07]3497,950 -NABjørk (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2022 1 Partial overlappingPartial overlapping 0.83[0.69; 0.99]68,9225,035 -NAMadley-Dowd_SE (Lamotrigine) (Controls unexposed, general pop) (Mixed indications), 2024 1 All studiesAll studies 0.88[0.77; 1.00]81,34719,9010%NAHernandez-Diaz (Lamotrigine) (Epilepsy), 2024 Madley-Dowd_SE (Lamotrigine) (Controls unexposed, general pop) (Mixed indications), 2024 Madley-Dowd_UK (Lamotrigine) (Controls unexposed, general pop) (Mixed indications), 2024 Bjørk (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2022 Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 Bromley (Lamotrigine) (Controls unexposed, sick), 2013 60.210.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-3.93.81.9870.000Hernandez-Diaz (Lamotrigine) (Epilepsy), 2024Madley-Dowd_SE (Lamotrigine) (Controls unexposed, general pop) (Mixed indications), 2024Madley-Dowd_UK (Lamotrigine) (Controls unexposed, general pop) (Mixed indications), 2024Bjørk (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2022Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020Bromley (Lamotrigine) (Controls unexposed, sick), 2013

Asymetry test p-value = 0.0208 (by Egger's regression)

slope=-0.3014 (0.0541); intercept=1.2302 (0.3324); t=3.7004; p=0.0208

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 8933, 12727, 17413, 17274

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.01[0.83; 1.23]119,38716,76736%NAMadley-Dowd_SE (Lamotrigine) (Controls unexposed, general pop) (Mixed indications), 2024 Madley-Dowd_UK (Lamotrigine) (Controls unexposed, general pop) (Mixed indications), 2024 Bjørk (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2022 Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 Bromley (Lamotrigine) (Controls unexposed, disease free), 2013 5 unexposed, sick controlsunexposed, sick controls 0.86[0.69; 1.07]48411,1140%NAHernandez-Diaz (Lamotrigine) (Epilepsy), 2024 Bjørk (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2022 Bromley (Lamotrigine) (Controls unexposed, sick), 2013 3 siblingssiblings 0.85[0.58; 1.24]--3%NAMadley-Dowd_SE (Lamotrigine) (Controls unexposed, sibling) (Mixed indications), 2024 Madley-Dowd_UK (Lamotrigine) (Controls unexposed, sibling) (Mixed indications), 2024 20.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Veroniki b (MA) (Autism Dyspraxia)Veroniki b (MA) (Autism Dyspraxia) Out of scale13.77[2.06; 188.00]-Wwhatever (meta-analysis)T11st trimesterstudies TTT2 metaPregmetaPreg 0.88[0.77; 1.00]0%19,901----Hernandez-Diaz (Lamotrigine) (Epilepsy), 2024 Madley-Dowd_SE (Lamotrigine) (Controls unexposed, general pop) (Mixed indications), 2024 Madley-Dowd_UK (Lamotrigine) (Controls unexposed, general pop) (Mixed indications), 2024 Bjørk (Lamotrigine) (Controls unexposed, sick) (Mixed indications), 2022 Coste (Lamotrigine) (Controls unexposed NOS) (Mixed indications), 2020 Bromley (Lamotrigine) (Controls unexposed, sick), 2013 60.510.01.0